Current research progress in targeted anti-angiogenesis therapy for osteosarcoma

Yun Liu1,2,3 | Nenggan Huang4 | Shijie Liao1,2,3 | Emel Rothzerg3,5 | Felix Yao3 | Yihe Li3 | David Wood3 | Jiake Xu3

Abstract

Osteosarcoma (OS) is the most common primary malignant bone tumour with a peak in incidence during adolescence. Delayed patient presentation and diagnosis is common with approximately 15% of OS patients presenting with metastatic disease at initial diagnosis. With the introduction of neoadjuvant chemotherapy in the 1970s, disease prognosis improved from 17% to 60%-70% 5-year survival, but outcomes have not significantly improved since then. Novel and innovative therapeutic strategies are urgently needed as an adjunct to conventional treatment modalities to improve outcomes for OS patients. Angiogenesis is crucial for tumour growth, metastasis and invasion, and its prevention will ultimately inhibit tumour growth and metastasis. Dysregulation of angiogenesis in bone microenvironment involving osteoblasts and osteoclasts might contribute to OS development. This review summarizes existing knowledge regarding pre-clinical and developmental research of targeted anti-angiogenic therapy for OS with the aim of highlighting the limitations associated with this application. Targeted anti-angiogenic therapies include monoclonal antibody to VEGF (bevacizumab), tyrosine kinase inhibitors (Sorafenib, Apatinib, Pazopanib and Regorafenib) and human recombinant endostatin (Endostar). However, considering the safety and efficacy of these targeted anti-angiogenesis therapies in clinical trials cannot be guaranteed at this point, further research is needed to completely understand and characterize targeted anti-angiogenesis therapy in OS.
1 | INTRODUCTION

Osteosarcoma (OS) is the most common primary malignant bone tumour. It is characterized by a high incidence of metastasis at the time of diagnosis most commonly with early haematogenous lung metastasis, a poor prognosis and a high incidence of recurrence. The use of neoadjuvant chemotherapy with multiple agents has improved the 5-year event-free-survival (EFS) of non-metastatic patients to over 70% while reducing the incidence of amputation by 10%-20%. However, with currently available treatment regimens, the overall 10-year survival rate is still less than 20% in metastatic patients. Despite being known as a highly aggressive cancer, treatment for OS has remained essentially unchanged for more than 30 years, underscoring a critical need for new treatment strategies.

Compared with traditional treatment methods, targeted therapy is a type of high selectivity and low toxicity cancer treatment that uses drugs or other substances to precisely identify and attack certain types of molecules that are involved in the growth and progression of cancer (eg proteins, nucleic acid fragments and gene products). Therefore, targeted therapies are currently the focus of much anti-cancer drug research and have been successfully applied to the treatment of chronic myeloid leukaemia, bowel, lung, breast and renal cancers.

In 1971, Folkman et al first described the concept that tumour growth and metastasis can be inhibited by blocking angiogenesis, establishing the basis of anti-angiogenesis therapy. Several studies have reported the effective use of anti-angiogenic agents such as bevacizumab in breast and cervical cancer and sorafenib in liver and thyroid cancer. In this review, we will be discussing the molecular pathogenesis of OS, giving insight to the specific molecules which may be targeted for the effective treatment of the disease.

2 | TUMOUR ANGIOGENESIS IN OS

Angiogenesis is a complex and highly adaptive process that is crucial for tumour growth and metastasis. The biological processes involved in angiogenesis include endothelial cell proliferation, differentiation and migration, recruitment of smooth muscle cells, smooth muscle cell maturation and migration of blood vessels, with the processes being strictly controlled by vascular regulatory factors. Vascular regulators include both angiogenic activators such as vascular endothelial growth factors (VEGF) and platelet-derived growth factors (PDGF), and inhibitors such as endostatin and angiostatin. An imbalance between vascular regulators will result in either angiogenesis or vascular degeneration. More than that, locally produced vascular regulatory factors in the bone microenvironment are critical to the regulation of bone homeostasis. Dysregulation of angiogenic and angiocrine activities could also lead to altered bone homeostasis, which may contribute to tumour development in bone microenvironment. Further, a hypoxic tumour cell environment has been reported to encourage angiogenesis in tumours by stimulating the overproduction of hypoxia inducible factor-1 (HIF-1) and VEGF. The activation of endothelial cells by angiogenic factors leads to the production of proteolytic enzymes which degrade the extracellular matrix. The degradation of the underlying basement membrane enables endothelial cells to proliferate and migrate to the surrounding tissue to form new vessels. These new vessels provide cancer cells with oxygen and nutrition and play an important role in cancer cell survival and metastasis. Thus, anti-angiogenic therapies, aimed to suppress these processes, may provide an interesting approach in OS therapeutics.

Possible targets for anti-angiogenesis therapies include transcription factors or signal pathways that directly or indirectly affect VEGF, PDGF, fibroblast growth factor (FGF), hepatocyte growth factor, integrin, cyclooxygenase (COX-2), metalloproteinasises (MMP-2, MMP-9) and HIF-1. VEGF and its receptors (VEGFRs) are key mediators of angiogenesis in cancer.

As the most studied marker of tumour neovascularization, VEGF and VEGFRs regulate both the development of blood vessels from precursor cells during embryogenesis (vasculogenesis), and the formation of blood vessels from pre-existing vessels (angiogenesis). It has also been shown to promote endothelium proliferation, inflammation and vascular permeability. The overexpression of VEGF is reported to be associated with disordered tumour neovascularization, destruction of endothelial cells, pericytes and basement membranes and has been implicated to promote cancer metastasis through the remodelling of microvasculature. VEGF as a therapeutic target has been validated in various types of human cancers.

Over-expression of VEGF and the resultant increase in angiogenesis have been reported in a number of human cancers including OS. VEGF levels correlate not only with the extent of tumour angiogenesis, but are a predictive measure of future metastases, and clinical prognosis. Currently, the mechanism by which the majority of anti-angiogenic drugs prevent tumour angiogenesis is by inhibiting the VEGF or VEGF/VEGFR signalling pathway, causing tumour cells to ‘starve’ by disrupting its blood supply. In addition, anti-angiogenic drugs may also play an anti-cancer role in the treatment of osteosarcoma by targeting other targets (Figure 1). The utilization of such angiogenesis inhibitors has been reported to be effective in pre-clinical trials and clinical treatments for OS (Table 1).

3 | ANTI-ANGIOGENIC TARGETED DRUGS FOR OS

Current management of non-metastatic OS is multimodal consisting of aggressive chemotherapy combined with radical surgical resection. Various combinations of adjuvant chemotherapeutic agents have been used, though the majority of recent trials still use high-dose methotrexate, doxorubicin, and cisplatin (MAP). The ‘sandwich’ therapy has reported 5-year EFS of 60%-70% for patients with non-metastatic OS. However, patients with metastatic tumours that respond poorly to chemotherapy, or those with recurrent disease, still present a major clinical challenge. The survival rate for these patients still does not exceed 20% post-therapy with established protocols. In recent years, with a better understanding of
the biology of OS growth and local environmental factors influencing disease progression, many studies have been conducted to identify possible therapeutic agents that could be of clinical use in the treatment of OS. These studies have focussed on the use of monoclonal antibody, tyrosine kinase inhibitors, recombinant human endostatin and traditional Chinese medicines. Here, we list some clinical trials of targeted anti-angiogenic drugs for OS (Table 2).

### 3.1 Monoclonal antibody

Monoclonal antibodies (mAb) are laboratory engineered proteins which serve as substitute antibodies that can restore, enhance or mimic the immune system’s attack on specific target cancer cells. mAb targeted drugs, which recognize and bind specific receptors or associated antigens on the surface of tumours, have been shown to improve the efficacy and reduce the toxic side effects of drugs in normal tissues.\(^{33,34}\) mAbs targeting VEGF was shown to drastically suppress tumour growth in vivo. The recombinant human VEGF mAb bevacizumab was approved for clinical use by the US Food and Drug Administration (FDA) in 2004 and is the first VEGF inhibitor to be approved for use in the treatment of cancer.\(^{35}\) It is a single-target anti-VEGF drug that binds to soluble VEGF, preventing receptor binding and inhibiting endothelial cell proliferation and vessel formation. It has been reported to be beneficial in solid tumours such as colorectal cancer, lung cancer, renal cell carcinoma and prostate cancer.\(^{36-39}\)

Several pre-clinical OS studies have confirmed the anti-angiogenesis and anti-cancer effects of bevacizumab in OS cell lines. Zhong ZY et al\(^{40}\) reported that bevacizumab significantly inhibited angiogenesis in OS, leading to cell apoptosis and a reduction in tumour size. The reported inhibition rate of bevacizumab on tumours is 32.87%, and this effect was synergistic with radiotherapy. Similarly, Zhao et al\(^{41}\) reported that bevacizumab had strong anti-angiogenic activity in a population of OS simulated nude mice strain, resulting in inhibition of tumour growth. Valery et al\(^{42}\) also reported the effective application of bavacizumab in the treatment of transplanted canine OS in mice. The authors suggested that the growth rate and microvascular density change observed in transplanted canine OS cells had a dose-dependent positive correlation with bevacizumab. This novel finding demonstrates its possible application as an effective neoadjuvant therapeutic agent for OS patients.
| Class               | Drug                        | In vitro or In vivo | Target                                                                 | Efficacy                                      | Refs. |
|--------------------|-----------------------------|---------------------|------------------------------------------------------------------------|-----------------------------------------------|-------|
| Monoclonal antibody | Bevacizumab                 | In vivo             | -                                                                      | Angiogenesis; growth↓ apotosis↑               | 40    |
|                    | Bevacizumab                 | In vivo             | -                                                                      | Angiogenesis; growth↓                        | 41    |
|                    | Bevacizumab                 | In vivo             | -                                                                      | Angiogenesis; growth↓                        | 42    |
| TKIs               | Sorafenib                   | In vitro and In vivo| ERK1/2; MCL-1; ezrin pathways                                         | Proliferation; angiogenesis; metastasis↓ apotosis↑ | 48    |
|                    | Sorafenib                   | In vitro            | VEGFR2; RET; MEK/ERK signalling pathway                                | Proliferation↓                               | 49    |
|                    | Sorafenib                   | In vitro            | -                                                                      | Proliferation; apoptosis↑                     | 50    |
|                    | Sorafenib+everolimus        | In vitro and In vivo| mTOR pathway                                                           | Proliferation; growth; metastasis↓ apotosis↑  | 56    |
|                    | Apatinib                    | In vitro and In vivo| VEGFR2/STAT3/BCL-2 signal pathway                                     | Proliferation; growth↓ apotosis↑             | 60    |
|                    | Apatinib+doxorubicin        | In vitro            | STAT3/Sox2 pathway                                                    | Chemoresistance↓; sensitivity to doxorubicin↑ | 62    |
|                    | Pazopanib+LDM topotecan     | In vitro and In vivo| -                                                                      | Angiogenesis; growth↓                         | 68    |
|                    | Pazopanib                   | In vitro and In vivo| VEGF                                                                   | Metastasis↓                                   | 22    |
| Endostatin          | Endostar+cisplatin          | In vivo             | VEGF;MMP-9                                                            | Proliferation; angiogenesis↓                  | 88    |
|                    | Endostar+combretastatin A4  | In vivo             | -                                                                      | Growth; angiogenesis↓                         | 89    |
|                    | phosphate                  |                     |                                                                         |                                               |       |
|                    | Endostar+doxiamycin         | In vivo             | -                                                                      | Growth; angiogenesis↓                         | 90    |
| Traditional Chinese herbal medicine | Modified Siwu decoction | In vivo             | VEGF; KDR; Flt-1                                                      | Growth; angiogenesis; metastasis↓             | 94    |
|                    | Thymoquinone                | In vitro and In vivo| NF-κB; XIAP; survivin; VEGF                                          | Growth; angiogenesis↓                         | 95    |
|                    | Cryptotanshinone            | In vitro            | VEGF                                                                   | Growth; angiogenesis↓                         | 96    |
|                    | Triptolide                  | In vitro            | Wnt/β-Catenin signalling                                             | Angiogenesis↓; Autophagy apoptosis↑           | 97    |

Note: ↑: Up-regulation, ↓: down-regulation.
| Class                  | Molecular targets | Therapy                        | Clinical trial | No. of patients | Outcome                                                                 | Refs. |
|------------------------|-------------------|--------------------------------|----------------|----------------|--------------------------------------------------------------------------|-------|
| Monoclonal antibody    | VEGF              | Bevacizumab+docetaxel+        | Phase I        | 8              | 3/8 CR; 2/8 PR; 2/8 SD; 1/8 PD                                           | 43    |
|                        |                   | gemcitabine                    |                |                |                                                                          |       |
|                        |                   | Bevacizumab+MAP                 | Phase II       | 31             | 4-year EFS 57.5 ± 10.0%; 4-year overall survival 83.4 ± 7.8%;           | 44    |
| TKIs                   | VEGFR1-3; RET; RAF| Sorafenib                      | Phase II       | 35             | 3/35 PR; 12/35 SD; 4-month PFS 46%; m-PFS 4 mo; overall survival 7 mo   | 51    |
|                        |                   | Sorafenib+Everolimus           | Phase II       | 38             | 2/8 PD; 2/8 SD; 5-year overall survival 64%                             | 52    |
|                        |                   | Sorafenib+denosumab            | -              | 1              | Complete metabolic remission                                           | 53    |
|                        |                   | Apatinib                       | Phase I        | 10             | 2/10 PR; 5/10 SD; ORR 20.0%; DCR 70.0%; 6-month PFS 60%; median overall survival 14 mo; m-PFS 7.5 mo | 54    |
|                        |                   | Apatinib                       | Phase II       | 37             | 16/37 PR; 4-month PFS 57%; m-PFS 4.5 mo; median overall survival 9.87 mo | 55    |
|                        | VEGFR; PDGFR-a/3; c-Kit | Pazopanib                      | Phase II       | 27             | ORR 25.93%; DCR 66.67%; m-PFS 3.5 mo; median overall survival 9.5 mo    | 56    |
|                        |                   | Pazopanib                       | -              | 3              | 3/3 CR                                                                  | 69    |
|                        |                   | Pazopanib                       | -              | 3              | 3/3 PR                                                                  | 70    |
|                        | VEGFR1-3; BRAF; KIT; PDGFRB; RAF; RET; AKT; ERK | Regorafenib                    | Phase I        | 3              | 1/3 PR                                                                  | 71    |
|                        |                   | Regorafenib                    | Phase II       | 26             | DCR 64%; PR 8%; m-PFS 16.4 wk                                          | 72    |
|                        |                   | Regorafenib                    | Phase II       | 42             | m-PFS 3.6 mo; 3/22 PR                                                   | 73    |
| Endostatin             | VEGF              | Endostar+chemotherapy          | Phase II       | 166            | 5-year EFS 70%                                                          | 91    |
|                        |                   | Endostar+chemotherapy          | Phase II       | 388            | 5-year overall survival 87%; 5-year DMFS 79%                            | 92    |
|                        |                   | Endostar+chemotherapy          | -              | 1              | PR                                                                      | 93    |

Abbreviation: EFS, event-free survival; PFS, progression-free survival; m-PFS, median progression-free survival; SD, stable disease; PR, partial response; ORR, objective response rate (complete response + partial response); CR, clinical response; DCR, disease control rate; DMFS, distant metastasis-free survival.
Many distinct escape mechanisms have been shown to protect malignant cells from immune recognition and destruction in the tumour microenvironment, and these mechanisms make the response from single-target drugs like bevacizumab short-lived. As a result, it is often used in combination with other chemotherapeutic drugs in clinical trials. In a single-centre trial using docetaxel, bevacizumab and gemcitabine for the treatment of high-risk sarcomas with metastasis and/or recurrence in adolescents/young adults, Kuo et al.\textsuperscript{23} reported that, among 8 patients with OS, only 3 achieved clinical remission, while 2 patients achieved partial response (PR), 2 patients had a stable disease (SD), and 1 patient had a progressive disease. The tumour control rate was 88\% (7/8), demonstrating the potential effectiveness of combining bevacizumab with other anti-tumour agents in the treatment of young patients with high-risk sarcomas.

Recently, a phase II clinical trial by Navid et al.\textsuperscript{46} reported a significant improvement in 4-year EFS and total survival rates among patients with limited resectable OS treated with bevacizumab + MAP. From a total of 31 patients with localized OS, the EFS and total survival rates were 57.5 ± 10.0\% and 83.4 ± 7.8\%, respectively, and 8 (28\%) of 29 evaluable patients had a histological response to preoperative chemotherapy. Of these patients, the addition of bevacizumab did not improve histological response, a strong predictor of outcome in OS, which correlated to no apparent improvement in EFS or overall survival.\textsuperscript{44} Authors also reported that approximately half of the study cohort experienced a reduction in wound healing which is a complex process that includes a vascularization phase similar to that supports tumour growth with VEGF and VEGFRs as key regulators.

Bevacizumab has been shown to normalize tumour vasculature both in the laboratory and in patients with other types of cancers and therefore improve access for chemotherapy. In combination with other chemotherapeutic agents, it has been shown to be efficacious in the treatment of several cancers clinically by increasing tumour response and prognosis. However, there is a need for further investigation to the use of bevacizumab alone or in combination with other agents, to demonstrate its efficacy in OS patients.

3.2 | Anti-angiogenic tyrosine kinase inhibitors (TKIs)

Tyrosine kinases are important mediators of the signalling cascade.\textsuperscript{45} It can be classified as either a receptor tyrosine kinase (RTKs) or non-receptor tyrosine kinase (NRTKs). The RTK family includes INSR and many growth factors (such as VEGF, FGF, PDGF and EGF) receptors.\textsuperscript{46} TKIs may be single- or multi-target inhibitors which have advantages and disadvantages related to pharmacokinetics, selectivity, potential resistance mechanisms and tumour environment. Since most tumours display multiple signalling pathways, many of the inhibitors in clinical development are multi-targeted to affect a wide range of targeted kinases increasing their efficacy and are less susceptible to the development of drug resistance. Recently, TKIs have received increased attention with major breakthroughs in their clinical applications, bringing hope to oncologists and cancer patients.\textsuperscript{13} Clinicians have attempted to apply TKIs for the development of targeted chemotherapies for OS, and some successes have been achieved for some of the agents, including sorafenib, apatinib, pazopanib and regorafenib, which have been reported to be effective in clinical trials. These results support the hypothesis that specific TKIs may be effective to regulate tumorigenesis and/or metastasis in OS.

3.2.1 | Sorafenib

Sorafenib is the first oral multi-kinase inhibitor that targets VEGFR-1, VEGFR-2 and VEGFR-3 to inhibit angiogenesis, the RET gene also known as RET/PTC rearrangement, RAF (including BRAFV600E) and platelet-derived growth factor receptors to inhibit tumour progression.\textsuperscript{47} Its use for the treatment of advanced renal cell carcinoma, hepatocellular carcinoma, acute myeloid leukaemia and thyroid carcinoma has been approved by the FDA. In a pre-clinical study, Ymera et al.\textsuperscript{48} reported that sorafenib inhibited the ERK1/2, MCL-1 and ERM signal pathways, and the proliferation of OS cells in a dose-dependent manner. It also induced apoptosis and inhibited the formation of new blood vessels. Mei et al.\textsuperscript{49} reported that sorafenib inhibits the proliferation of OS cells by influencing the VEGFR2, RET and MEK/ERK signalling pathways. In addition, Wolfsberger et al.\textsuperscript{50} reported that sorafenib showed potent anti-tumour activity against canine OS cells in vitro, suggesting its therapeutic potential as a tool in the management of bone cancer in dogs.

Three studies to date have evaluated the clinical efficacy of sorafenib alone for the treatment of OS. A phase II trial of sorafenib by the Italian Sarcoma Group in 2012\textsuperscript{51} reported that of 35 patients aged >14 years enrolled with recurrent/unresectable tumours who received sorafenib, progression-free survival at 4 months was 46\%. Although some unprecedented long-lasting responses were achieved, for the majority its effect was short-lived with only 29\% of patients reported to have stabilized progression at 6 months. In another trial, 3 out of 4 patients with relapsed OS post-chemotherapy who obtained treatment with sorafenib had SD with a median response time of 3 months, after which their condition deteriorated.\textsuperscript{52} Furthermore, a study done in Poland by Raciborska et al.\textsuperscript{53} reported that among 8 patients with refractory OS with a median age of 18 years, treatment with sorafenib achieved remission in 6 patients with an overall response rate of 75\%. There were no serious toxicities, and sorafenib was well tolerated in young patients with bone tumours. In summary, these trials show that sorafenib was able to temporarily inhibit OS progression, although the benefit was minimal and short-lived. Therapy with sorafenib alone demonstrated temporary tumour stabilization in OS, indicating that more effective combination treatment regimens are required to achieve permanent remission.

Oncogenic activation of mTOR signalling significantly contributes to the progression of different types of cancers including OS, and the PI3K/Akt/mTOR pathway has been implicated in the metastatic behaviour of OS.\textsuperscript{54,55} In 2013, a pre-clinical study by Pignochino et al.\textsuperscript{56} confirmed that the lack of efficacy of sorafenib as
a single agent has been attributed to its action on the mTOR pathway, so the coadministration of sorafenib with an mTOR inhibitor may improve its effectiveness. Subsequently, Pignochino et al\(^57\) conducted a non-randomized phase 2 clinical trial. They achieved a 10% overall response rate when treating adults with advanced recurrent/unresectable disease with combination treatment of sorafenib and everolimus, though the benefits were unsustained and did not attain the prespecified target of 6-month progression-free survival (PFS) of 50% or greater.

Cathomas et al\(^58\) looked at the role of receptor activator of nuclear factor-kB ligand (RANKL) inhibitors in addition to sorafenib as a combination treatment option for unresectable OS after chemotherapy. The authors reported complete sustained metabolic remission ongoing for over 18 months following treatment with sorafenib and denosumab. This finding confirms pre-clinical data on RANK/ RANKL inhibition in OS, but larger clinical trials are required to determine its efficacy in this patient population.

Although sorafenib is a relatively new drug, it is now considered first-line treatment for advanced hepatocellular carcinoma and renal cell carcinoma. Its effect on OS has yet been studied on a large scale, and more clinical data are needed to properly assess its efficacy as a possible treatment option particularly for patients with metastatic disease and refractory OS. Current studies have demonstrated that the effect of sorafenib as a monotherapy for OS patients was unsustainable. Different pathways involved in the pathogenesis of OS warrant further investigation looking at multiple-targeted therapeutic approaches which may yield major improvements in the management of the disease.

### 3.2.2 Apatinib

Apatinib is a small molecule tyrosine kinase inhibitor that highly and selectively targets VEGFR-2 and also inhibits the activities of VEGFR-1, Kit, c-SRC and RET,\(^59\) leading to the inhibition of endothelial cell migration and proliferation, and decrease in tumour microvascular density. Compared with sorafenib, its effects on VEGF mediated endothelial cell migration and proliferation are more potent. It is also considerably cheaper as an alternative anti-tumour agent. In the related study of OS, Liu et al\(^60\) reported that apatinib induced autophagy and apoptosis in OS by the inactivation of the VEGFR2/STAT3/BCL-2 signalling pathway. When combined with autophagy inhibitors, its anti-tumour effects were further enhanced. Signal transducers and activators of transcription 3 (STAT3) has been implicated as an oncogene and therapeutic target in a variety of neoplastic diseases including OS.\(^61\) In line with this, a recent study reported that apatinib inhibits SRY-Box Transcription Factor 2 (Sox2) via the STAT3 signalling pathway, significantly reducing the doxorubicin-induced stem phenotype and metastasis of OS cells and providing a new therapeutic strategy for overcoming adriamycin-induced drug resistance in the treatment of OS.\(^62\) Unfortunately, the anti-angiogenic effect of apatinib has not been demonstrated in pre-clinical studies of OS.

Apatinib is reported to be safe and efficacious to use in patients with advanced OS. Clinical trials by Zhou et al\(^63\) reported that apatinib showed promising efficacy and an acceptable safety profile in a trial of patients with metastatic OS. In this study, a patient with pulmonary metastases achieved PR 11 months post-treatment without any serious drug-related side effects. Zheng et al\(^64\) suggested that apatinib treatment as a single agent in 10 patients with advanced OS with pulmonary metastases, whose first-line chemotherapy had failed, resulted in a 60% PFS and 70.0% disease control rate (DCR) at six months. The median PFS was 7.5 months and median overall survival was 14 months, indicating that apatinib is an effective single-drug treatment option for patients with OS and associated pulmonary metastases, though randomized controlled trials based on this data are required to further evaluate apatinib activity. Phase II clinical trial of 37 patients with progressive relapsed or unresectable OS by Lu et al\(^65\) treated with apatinib found an objective response rate (ORR) of 43.24% (16/37) and a 4-month PFS rate of 56.76% (95% CI, 39.43%-70.84%). The authors also reported a median progression-free survival (m-PFS) and total survival rate of 4.50 months (95% CI, 3.47-6.27) and 9.87 months (95% CI, 7.97-18.93), respectively, confirming its high objective efficacy and low toxicity. Another review of 27 OS cases treated with an initial apatinib dose of 500 mg/qd by Tian et al\(^66\) found an ORR of 25.93% and DCR of 66.67%. This study reported a median progression-free survival of 3.5 months (95% CI, 2.5-4.8 months), and median overall survival of 9.5 months (95% CI, 7.8-10.5 months).

For patients with advanced OS non-responsive to chemotherapy, apatinib proved to be effective in prolonging PFS in previous multi-centre trials and was consequently added to the National Comprehensive Cancer Network guidelines in the United States as a second-line therapy. However, it must be noted that these promising results have been limited to mostly retrospective studies with small population sizes without controls. Additional studies are needed to fully calculate the efficacy of apatinib for the treatment of OS.

### 3.2.3 Pazopanib

Pazopanib, a second-generation multi-target TKI, is approved for the treatment of soft tissue sarcomas and has a high affinity for VEGF receptors including PDGFR-a/3 and c-Kit receptors.\(^67\) Sushil et al\(^68\) reported that pazopanib exerts its anti-cancer effect through the inhibition of both angiogenic and oncogenic signal pathways in OS mouse models. The anti-angiogenic effects of pazopanib were significantly enhanced when combined with the chemotherapy drug Topotecan. Tanaka et al\(^22\) showed that daily administration of pazopanib given to C3H mice bearing LM8 OS xenografts reduced the rate and size of pulmonary metastasis. Pazopanib inhibited the destruction of vascular barriers preventing trans-endothelial migration of tumour cells, leading to a reduced incidence of pulmonary metastases in vivo.

A few studies have suggested that the use of pazopanib as an inhibitor of these tyrosine kinases can lead to an improved clinical
response. A study by Danish researchers\(^69\) reported PR in 3 patients with advanced osteogenic sarcoma following treatment with pazopanib. Umeda et al\(^70\) described 3 patients with recurrent OS who survived for more than 21 months after treatment with pazopanib. There are also ongoing clinical trials and unreported completed trials looking at pazopanib as a viable therapeutic option for OS patients.\(^71\) So far, these studies have shown that pazopanib exhibited favourable clinical benefit and a tolerable toxicity profile compared to other TKIs.

These reports indicate that pazopanib has strong anti-tumour activity and may contribute to improved survival. The response rates, PFS and overall survival are comparable with the efficacy shown using sorafenib alone or in combination with everolimus. The toxicity profile of pazopanib also appeared to be acceptable for treatment. Recently, pazopanib was approved for second-line treatment in non-adiopocytic soft tissue sarcoma (STS) after failure of standard chemotherapy based on the PALETTE study—a double-blind, randomized, phase 3 trial which was conducted globally comparing the efficacy of pazopanib versus placebo for the treatment of metastatic STS.\(^72,73\) Despite data suggesting that pazopanib can stabilize disease, the PFS and overall survival are was still poor for patients with metastatic OS. Future studies on pazopanib alone or in combination with chemotherapy and/or radiation therapy could be investigated in a randomized trial.

### 3.2.4 | Regorafenib

Regorafenib is a small molecule multi-kinase inhibitor, which inhibits the activity of VEGFR1-3, KIT, PDGFRB, RAF, RET and BRAF, and has been demonstrated to increase the overall survival of patients with US FDA approval for use in metastatic colorectal cancer, advanced gastrointestinal stromal tumours and hepatocellular carcinoma.\(^75,76\) It has also been theorized to inhibit the progression of OS by inhibiting AKT and ERK-mediated signalling pathways. Its biochemical characteristics are similar to sorafenib, though its pharmacological effects are noticeably stronger.\(^77,78\) Regorafenib has shown some significant results in clinical trials of OS. However, the anti-angiogenesis mechanism in the disease has not yet been illustrated.

Phase I clinical trials conducted by Klaus et al\(^79\) showed that one third of patients with advanced OS achieved PR with regorafenib treatment, providing a preliminary evidence of its safety and anti-tumour capabilities. Subsequent non-comparative, double-blind, placebo-controlled, phase 2 trial done by Duffaud et al\(^80\) found that regorafenib was well tolerated. The regorafenib group also achieved a median PFS of 16.4 weeks, a DCR 65% and a PR in 8% of patients. A second randomized, double-blinded, phase II study\(^81\) reported that regorafenib improved the progression time of adult progressive metastatic OS compared with placebo (m-PFS of 3.6 months and 1.7 months, respectively). The authors concluded that regorafenib demonstrated clinically meaningful anti-tumour activity in adult patients with recurrent, progressive, metastatic OS after failure of conventional chemotherapy, with a positive effect on delaying disease progression. It is possible that regorafenib may have an important role as a therapeutic agent complementary to the standard regimens used against OS.

### 3.3 | Endostatin

Endostatin, isolated from a culture medium of rat endothelio by O’Reilly MS et al in 1997,\(^82\) is an endogenous protein which is a potent inhibitor of VEGF expression and angiogenesis.\(^83\) In 2005, Endostar (ES) or human recombinant endostatin was developed independently and first used therapeutically for lung, nasopharyngeal and malignant tumours of the digestive system.\(^84-86\) Recombinant human endostatin is considered safe for clinical use and displays multi-target tumour suppression potential through the inhibition of VEGF expression, and the activation of ERK, AKT and MAPK pathways.\(^87\) Recent studies demonstrated the clinical benefit of ES as an anti-angiogenesis therapeutic agent for OS when used in combination with other chemotherapy agents.

Pre-clinical studies reported that the combination of ES and chemotherapy agents significantly inhibited tumour angiogenesis and growth. Zhang XL et al\(^88\) reported that the combination of ES and cisplatin inhibited the growth of OS via the inhibition of VEGF and MMP-9 expression. Fu et al\(^89\) reported that the combination of the anti-angiogenesis agent ES and the vascular disrupting agents (VDA), combretastatin A4 phosphate (CA4P), had a good anti-tumour and anti-angiogenesis effect in OS mice models, with no significant toxicity. Synergistic anti-tumour effects of ES with doxorubicin and Adriamycin have also been reported in OS mice models.\(^90\)

The anti-tumour activity of ES has been demonstrated in clinical trials. Xu et al\(^91\) evaluated the clinical efficacy of ES combined with chemotherapy in the treatment of OS. In a group of 116 newly diagnosed patients with OS enrolled to receive chemotherapy with or without ES, there was no significant difference in the histological response between the ES treatment and non-treatment groups. However, ES treatment significantly inhibited the expression of VEGF and presence of micro-vessels induced by chemotherapy. ES treatment did not affect the overall survival rate, but increased the EFS rate and reduced the occurrence of metastases. A recent non-randomized controlled trial reported that 388 patients with non-metastatic conventional OS, who were treated with ES combined with chemotherapy, achieved significantly increased 5-year metastasis-free survival rate of 79% (versus 61% in the control group) and a 5-year survival rate of 87% (versus 74% in the control group).\(^92\) Moreover, a study by Jiang et al\(^93\) reported that a paediatric OS patient with pulmonary metastasis and malignant pleural effusion, who was treated with surgical resection combined with ES and chemotherapy, obtained pathologic complete remission and was in PFS. The experiences above indicate that ES combined with chemotherapy had significant activity to increase survival rates in patients with advanced sarcomas, with tolerable side effects, and warrant further investigation for future therapeutic regimens.
3.4 | Traditional Chinese herbal medicine

In recent years, the synergistic effects of traditional Chinese herbal medicine (CHM) combined with radio- and chemotherapy have been gaining increasing significance as its effectiveness as an anti-angiogenetic agent are being explored. Huang YM et al\textsuperscript{105} showed that the modified Siwu decoction, a traditional Chinese medical formula, prevents the growth and metastasis of malignant bone tumour in vivo via the inhibition of VEGF, KDR, Flt-1 expression and angiogenesis in a dose-dependent manner. Peng et al\textsuperscript{95} reported that thymoquinone, an extract of black fennel, could inhibit tumour angiogenesis and growth via the inhibition of NF-xB and its regulatory molecules. Xu YM et al\textsuperscript{96} also reported that the fat-soluble effective monomer cryptotanshinone, derived from the plant salvia miltiorrhiza (also known as red sage), can effectively reduce the level of VEGF expression in OS cells, thus inhibiting angiogenesis. Moreover, a recent study by Li et al\textsuperscript{97} reported that triptolide, the active natural product isolated from the medicinal plant Tripterygium wilfordii, can inhibit angiogenesis and induce apoptosis of OS cells by inhibiting the expression of HIF-1 and VEGF via the Wnt/catenin signalling pathway. Collectively, these studies demonstrate that traditional Chinese medicines have the potential to become an adjunct treatment for OS and other malignancies in combination with conventional regimens by promoting anti-angiogenesis effects. However, the majority of these studies have only been conducted in vitro, and significant further investigative studies are required to determine its efficacy in vivo.

4 | SUMMARY AND FUTURE PROSPECTS

There is no established systemic treatment option for advanced or unresectable OS progressing after standard chemotherapy, and as such, the survival rate of patients with OS has not improved significantly in recent years. Angiogenesis is a key factor affecting tumour growth and metastasis, and theoretically, anti-angiogenetic therapeutic agents present potentially novel therapies for various cancer types. Recently, progress has been made in the development and application of targeted anti-angiogenetic drugs, providing much-needed relief in the search of therapeutic alternatives for OS patients. Much of this research has focussed on cases of refractory and/or metastatic disease following failed traditional chemotherapy and surgical resection. However, the search for alternative targeted anti-angiogenetic regimens is still in its infancy and a long way from achieving desired clinical applications. New research has generated plenty of excitement, but still faces a myriad of questions before it can be widely adopted for clinical use. For instance, how do we predict the therapeutic effect of an anti-angiogenetic targeted therapeutic agent for OS, and which combination of new agent with traditional therapies would be most effective. More detailed clinical studies are needed to establish reasonable norms and guidelines for the application of these plausible therapeutic alternatives. With much-needed technological developments and extensive research, targeted anti-angiogenesis therapy could become a potent and effective weapon in our fight to effectively manage patients with OS.

ACKNOWLEDGEMENTS

Dr Yun Liu and Shijie Liao were visiting scholars to Jiake Xu’s laboratory at the University of Western Australia.

CONFLICT OF INTEREST

All authors declare that they have no conflict of interest.

AUTHOR CONTRIBUTIONS

Yun Liu and Nenggan Huang conducted research and drafted the manuscript. Shijie Liao, Emel Rothzerg, Yihe Li and Felix Yao provided assistance in the process of revised drafting manuscript and figure and tables construction. David Wood and Jiake Xu contributed to conceptual framework, supervised the study and revised the manuscript.

DATA AVAILABILITY STATEMENT

The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID

Emel Rothzerg https://orcid.org/0000-0003-1957-930X
Jiake Xu https://orcid.org/0000-0003-2021-8309

REFERENCES

1. Moore DD, Luu HH. Osteosarcoma. Cancer Treat Res. 2014;162:65-92.
2. Friebele JC, Peck J, Pan X, Abdel-Rasoul M, Mayerson JL. Osteosarcoma: a meta-analysis and review of the literature. Am J Orthop (Belle Mead NJ). 2015;44(12):547-553.
3. Kempf-Bielack B, Bielack SS, Jürgens H, et al. Osteosarcoma relapse after combined modality therapy: an analysis of unsel ected patients in the Cooperative Osteosarcoma Study Group (COSS). J Clin Oncol. 2005;23(3):559-568.
4. Takeoka H, Yamada K, Naito Y, et al. Phase II trial of carboplatin and pemetrexed plus bevacizumab with maintenance bevacizumab as a first-line treatment for advanced non-squamous non-small cell lung cancer in elderly patients. Anticancer Res. 2018;38(6):3779-3784.
5. Kantarjian HM, Hughes TP, Larson RA, et al. Correction to: Long-term outcomes with front line nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021;35(2):440-453.
6. Drapkin BJ, Minna JD. A rational targeted therapy for platinum-resistant small-cell lung cancer. Cancer Cell. 2021;39(4):453-456.
7. Choueiri TK, Kaelin WG Jr. Targeting the HIF2-VEGF axis in renal cell carcinoma. Nat Med. 2020;26(10):1519-1530.
8. Chang L, Ruiz P, Ito T, Sellers WR. Targeting pan-essential genes in cancer: challenges and opportunities. Cancer Cell. 2021;39(4):466-479.
9. Folkman J. Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285(21):1182-1186.
10. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov. 2004;3(6):391-400.
11. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med. 2007;356(2):125-134.
12. Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases. *Physiol Rev*. 2011;91(3):1071-1121.

13. Qin S, Li A, Yi M, Yu S, Zhang M, Wu K. Recent advances on antiangiogenesis receptor tyrosine kinase inhibitors in cancer therapy. *J Hematol Oncol*. 2019;12(1):27.

14. Zhang J, Zhang J, Yan Z, et al. Recombinant humanized endostatin. *Theranostics*. 2020;10(13):5957-5965.

15. Alfranca A, Martinez-Cruzado L, Tornin J, et al. Bone microenvironment signals in osteosarcoma development. *Cell Mol Life Sci*. 2015;72(16):3097-3113.

16. Egners A, Rezaei M, Kuzmanov A, et al. PHD3 acts as tumor suppressor in mouse osteosarcoma and influences tumor vascularization via PDGF-C signaling. *Cancers (Basel)*. 2018;10(12):496.

17. Yang J, Yang D, Sun Y, et al. Genetic amplification of the vascular endothelial growth factor (VEGF) and fibroblast growth factor 2 (FGF-2): Promising targets for the treatment of cancer. *Cancer*. 2020;21(2):455.

18. Li YS, Liu Q, Tian J, He HB, Luo W. Angiogenesis process in osteosarcoma: an updated perspective of pathophysiology and therapeutics. *Am J Med Sci*. 2019;357(4):280-288.

19. Egners A, Rezaei M, Kuzmanov A, et al. PHD3 acts as tumor suppressor in mouse osteosarcoma and influences tumor vascularization via PDGF-C signaling. *Cancers (Basel)*. 2018;10(12):496.

20. Zhang J, Zhang J, Yan Z, et al. Loss of HIF-1alpha in endothelial cells disrupts a hypoxia-driven VEGF autocrine loop necessary for tumorigenesis. *Cancer Cell*. 2004;6(5):485-495.

21. Su Y, Gao L, Teng L, et al. Id1 enhances human ovarian cancer endothelial progenitor cell angiogenesis via PI3K/Akt and NF-xbB/MMP-2 signaling pathways. *J Transl Med*. 2013:11:132.

22. Tanaka T, Yui Y, Naka Y, et al. Dynamic analysis of lung metastasis by mouse osteosarcoma LM8: VEGF is a candidate for anti-metastasis therapy. *Clin Exp Metastasis*. 2013;30(4):369-379.

23. Weis S, Cui J, Barnes L, Chersed D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. *J Cell Biol*. 2004;167(2):223-229.

24. Laddha AP, Kulkarni YA. VEGF and FGF-2: Promising targets for the treatment of respiratory disorders. *Respir Med*. 2019;156:33-46.

25. Yang SY, Yu H, Krygier JE, Wooley PH, Mott MP. High VEGF with rapid growth and early metastasis in a mouse osteosarcoma model. *Sarcoma*. 2007;2007:95628.

26. Yang J, Yang D, Sun Y, et al. Genetic amplification of the vascular endothelial growth factor (VEGF) pathway genes, including VEGFA, in human osteosarcoma. *Cancer*. 2011;117(21):4925-4938.

27. Mukherjee A, Madamsetty VS, Paul MK, Mukherjee S. Recent advancements of nanomedicine towards antiangiogenic therapy in cancer. *Int J Mol Sci*. 2020;21(2):455.

28. Xing P, Zhang J, Yan Z, et al. Recombined humanized endostatin (Endostar) combined with chemotherapy for advanced bone and soft tissue sarcomas in stage IV. *Oncotarget*. 2017;8(22):36716-36727.

29. Kaya M, Wada T, Nagoya S, Yamashita T. Prevention of postoperative progression of pulmonary metastases in osteosarcoma by antiangiogenic therapy using endostatin. *J Orthop Sci*. 2007;12(6):562-567.

30. Harrison DJ, Geller DS, Gill JD, Lewis VO, Gorlick R. Current and future therapeutic approaches for osteosarcoma. *Expert Rev Anticancer Ther*. 2018;18(1):39-50.

31. Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. *J Clin Oncol*. 2005;23(9):2004-2011.

32. Hagleitner MM, de Bont ES, Te Loo DM. Survival trends and long-term toxicity in pediatric patients with osteosarcoma. *Sarcoma*. 2012;2012:636405.
52. Penel-Page M, Ray-Coquard I, Larcombe J, et al. Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC’S (Observatoire de l’Utilisation des Thérapies Ciblées dans les Sarcomes). BMC Cancer. 2015;15:854.

53. Raciborska A, Bliska K. Sorafenib in patients with progressed and refractory bone tumors. Med Oncol. 2018;35(10):126.

54. Zhang B, Wu J, Guo P, et al. Down-regulation of SREBP via PI3K/AKT/mTOR pathway inhibits the proliferation and invasion of non-small-cell lung cancer cells. Onco Targets Ther. 2020;13:8951-8961.

55. Song R, Tian K, Wang W, Wang L. P53 suppresses cell proliferation, metastasis, and angiogenesis of osteosarcoma through inhibition of the PI3K/AKT/mTOR pathway. Int J Surg. 2015;20:80-87.

56. Pignochino Y, Dell’Aglio C, Basiricò M, et al. The combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 up-regulation in osteosarcoma preclinical models. Clin Cancer Res. 2013;19(8):2117-2131.

57. Grignani G, Palmerini E, Ferraresi V, et al. Sorafenib and everolimus in patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial. Lancet Oncol. 2015;16(1):98-107.

58. Cathomas R, Rothermundt C, Bode B, Fuchs B, von Moos R, von Schewitter M. RANK ligand blockade with denosumab in combination with sorafenib in chemorefractory osteosarcoma: a possible step forward? Oncology. 2015;88(4):257-260.

59. Tian S, Quan H, Xie C, et al. YN968D1 is a novel and selective inhibitor of vascular endothelial growth factor receptor-2 tyrosine kinase with potent activity in vitro and in vivo. Cancer Sci. 2011;102(7):1374-1380.

60. Liu K, Ren T, Huang Y, et al. Apatinib promotes autophagy and apoptosis through VEGFR2/STAT3/BCL-2 signalling in osteosarcoma. Cell Death Dis. 2017;8(8):e3015.

61. Liu Y, Liao S, Bennett S, et al. STAT3 and its targeting inhibitors in osteosarcoma. Cell Prolif. 2021;54(2):e12974.

62. Tian ZC, Wang JQ, Ge H. Apatinib ameliorates doxorubicin-induced migration and cancer stemness of osteosarcoma cells by inhibiting Sox2 via STAT3 signalling. J Orthop Translat. 2020;22:132-141.

63. Zhou Y, Zhang W, Tang F, et al. A case report of apatinib in treating osteosarcoma with pulmonary metastases. Medicine (Baltimore). 2017;96(15):e5678.

64. Zheng K, Xu M, Wang L, Yu X. Efficacy and safety of apatinib in advance osteosarcoma with pulmonary metastases: a single-center observational study. Medicine (Baltimore). 2018;97(31):e11734.

65. Xie L, Xu J, Sun X, et al. Apatinib for advanced osteosarcoma after failure of standard multimodal therapy: an open label phase II clinical trial. Oncologist. 2019;24(7):e542-e550.

66. Tian Z, Gu Z, Wang X, et al. Efficacy and safety of apatinib in treatment of osteosarcoma after failed standard multimodal therapy: an observational study. Medicine (Baltimore). 2019;58(19):e15650.

67. Frampton JE. Pazopanib: a review in advanced renal cell carcinoma. Target Oncol. 2017;12(4):543-554.

68. Kumar S, Mokhtari RB, Sheikh R, et al. Metronomic oral topotecan with pazopanib is an active antiangiogenic regimen in mouse models of aggressive pediatric solid tumor. Clin Cancer Res. 2011;17(17):5656-5667.

69. Safwat A, Boysen A, Lücke A, Rossen P. Pazopanib in metastatic osteosarcoma: significant clinical response in three consecutive patients. Acta Oncol. 2014;53(10):1451-1454.

70. Umeda K, Kato I, Saida S, Okamoto T, Adachi S. Pazopanib for second recurrence of osteosarcoma in pediatric patients. Pediatr Int. 2017;59(8):937-938.

71. Longhi A, Paioli A, Palmerini E, et al. Pazopanib in relapsed osteosarcoma patients: report on 15 cases. Acta Oncol. 2019;58(1):124-128.

72. Kasper B, Sleijfer S, Littérè S, et al. Long-term responders and survivors on pazopanib for advanced soft tissue sarcomas: subanalysis of two European Organisation for Research and Treatment of Cancer (EORTC) clinical trials 62043 and 62072. Ann Oncol. 2014;25(3):719-724.

73. Lee ATJ, Jones RL, Huang PH. Pazopanib in advanced soft tissue sarcomas. Signal Transduct Target Ther. 2019;4:16.

74. Benson C, Ray-Coquard I, Steijfer S, et al. Outcome of uterine sarcoma patients treated with pazopanib: a retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072. Gynecol Oncol. 2016;142(1):89-94.

75. Mirone G, Perna S, Shukla A, Marfe G. Involvement of Notch-1 in resistance to Regorafenib in colon cancer cells. J Cell Physiol. 2021;235(10):1079-1105.

76. Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303-312.

77. Harrison DJ, Gill JD, Roth ME, et al. Initial in vivo testing of a multitarget kinase inhibitor, regorafenib, by the Pediatric Preclinical Testing Consortium. Pediatr Blood Cancer. 2020;67(6):e28222.

78. Pan PJ, Liu YC, Hsu FT. Protein kinase B and extracellular signal-regulated kinase inactivation is associated with Regorafenib-induced inhibition of osteosarcoma progression in vitro and in vivo. J Clin Med. 2019;8(6):900.

79. Mross K, Frost A, Steinbild S, et al. A Phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012;18(9):2658-2667.

80. Duffaud F, Mir O, Boudou-Rouquette P, et al. Efficacy and safety of regorafenib in adult patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, placebo-controlled, phase 2 study. Lancet Oncol. 2019;20(1):120-133.

81. Davis LE, Bolejack V, Ryan CW, et al. Randomized double-blind phase II study of regorafenib in patients with metastatic osteosarcoma. J Clin Oncol. 2019;37(16):1424-1431.

82. O’Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell. 1997;88(2):277-285.

83. Kim HS, Lim SJ, Park YK. Anti-angiogenic factor endostatin in osteosarcoma. Apmis. 2009;117(10):716-723.

84. Ni Q, Ji H, Zhao Z, Fan X, Xu C. Endostar, a modified endos...
91. Xu M, Xu CX, Bi WZ, et al. Effects of endostar combined multidrug chemotherapy in osteosarcoma. Bone. 2013;57(1):111-115.
92. Xu H, Huang Z, Li Y, Zhang Q, Hao L, Niu X. Perioperative rh-endostatin with chemotherapy improves the survival of conventional osteosarcoma patients: a prospective non-randomized controlled study. Cancer Biol Med. 2019;16(1):166-172.
93. Jiang S, Wang G, Dong Y. Endostar combined with chemotherapy in a pediatric osteosarcoma with pulmonary metastasis and malignant pleural effusion: a case report. Medicine (Baltimore). 2017;96(51):e9077.
94. Huang YM, He RR, Liu JW, et al. Effects of modified Siwu decoction on expressions of VEGF and its receptors in osteosarcoma-bearing mice. Chinese J Trad Med Traumatol Orthop. 2009;17(03):1-3.
95. Peng L, Liu A, Shen Y, et al. Antitumor and anti-angiogenesis effects of thymoquinone on osteosarcoma through the NF-κB pathway. Oncol Rep. 2013;29(2):571-578.
96. Xu Y, Ji Q, Zhang Q, Wang Y. Cryptotanshinone down-regulates the expression of VEGF and inhibits angiogenesis in U2OS osteosarcoma cells. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2016;32(1):29-33.
97. Li X, Lu Q, Xie W, Wang Y, Wang G. Anti-tumor effects of triptolide on angiogenesis and cell apoptosis in osteosarcoma cells by inducing autophagy via repressing Wnt/β-Catenin signaling. Biochem Biophys Res Commun. 2018;496(2):443-449.

How to cite this article: Liu Y, Huang N, Liao S, et al. Current research progress in targeted anti-angiogenesis therapy for osteosarcoma. Cell Prolif. 2021;54:e13102. https://doi.org/10.1111/cpr.13102